RT Journal Article
T1 CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales
A1 Rodriguez-Baño, Jesus
A1 Gutierrez-Gutierrez, Belen
A1 Pascual, Alvaro
K1 Ceftriaxone
K1 Carbapenems
K1 Cephamycins
K1 Lactams
K1 Infections
K1 Piperacillin/tazobactam
K1 Pneumonia
AB Carbapenems are considered the drugs of choice for the treatment of serious infections caused by ceftriaxone-resistant Enterobacterales. However, because of the dramatic increase in carbapenem-resistant organisms worldwide, finding alternatives to carbapenems is a must. The potential options include β-lactam/β-lactamase inhibitor combinations, temocillin, cephamycins and some non-β-lactam drugs. The most controversial is piperacillin/tazobactam; the results of the MERINO trial are challenged because the isolates of patients with worse outcomes were frequently not susceptible to piperacillin/tazobactam when studied by reference methods, and also because the drug was not administered in extended infusion. Other potential options are briefly discussed. We conclude that carbapenems are not necessary for all patients with infections caused by ceftriaxone-resistant Enterobacterales.
PB Oxford University Press
YR 2021
FD 2021-02-24
LK http://hdl.handle.net/10668/4290
UL http://hdl.handle.net/10668/4290
LA en
NO Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Pascual A. CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales. JAC Antimicrob Resist. 2021 Feb 24;3(1):dlaa112
DS RISalud
RD Apr 20, 2025